Bruker Corporation - BRKR STOCK NEWS

Bruker Corporation (Nasdaq: BRKR) reported first-quarter revenues of $554.7 million, up 30.8% year-over-year from $424.0 million. Organic growth was 23.8%, with foreign currency effects contributing 6.2%. Bruker Scientific Instruments saw revenues rise 32.7% to $506.2 million, while Bruker Energy & Supercon Technologies increased 13.4% to $52.4 million. GAAP operating income surged to $89.1 million with a margin of 16.1%, and EPS reached $0.37. The company raised its FY 2021 guidance, expecting 14%-16% revenue growth and non-GAAP EPS of $1.82 to $1.87.

Bruker Corporation (Nasdaq: BRKR) reported preliminary revenue for Q1 2021 between $549 million and $554 million, reflecting 30% to 31% growth year-over-year. Excluding effects from currency fluctuations and acquisitions, the non-GAAP organic revenue growth is estimated at 22% to 23%, exceeding earlier forecasts of 15%. Revenue growth was attributed to strong performance in all three Bruker Scientific Instrument groups, including notable sales of GHz-class NMR systems. Full financial results are expected on May 5, 2021.

Bruker Corporation (Nasdaq: BRKR) announced the addition of a 1.2 GHz Avance nuclear magnetic resonance (NMR) spectrometer at Forschungszentrum Juelich (FZJ), Germany. This new technology enhances research capabilities in neurodegenerative diseases, particularly Alzheimer's, by improving the structural analysis of protein-ligand interactions. The installation boosts the sensitivity and resolution of NMR studies, facilitating advancements in antibiotic development and understanding of molecular mechanisms. Initial results show promising progress in obtaining spectra from valuable disease research samples.

Bruker Corporation (Nasdaq: BRKR) has launched several magnetic resonance systems, including the Fourier™ 80, a high-performance 80 MHz FT-NMR benchtop spectrometer, aimed at enhancing accessibility for pharma, chemical, and food research. The AvanceCore 400, a cost-effective 400 MHz NMR system, is also introduced to broaden accessibility. Additionally, the Magnettech ESR 5000 benchtop EPR system offers compact performance for various applications. These innovations are designed to improve data quality and increase throughput in research labs.

Bruker Corporation (Nasdaq: BRKR) has announced the installation of two MuVi™ and LCS SPIM™ light-sheet microscopes at Memorial Sloan Kettering Cancer Center (MSK). Funded by Cycle for Survival, these microscopes will enhance cancer research by allowing scientists to visualize cellular and tissue characteristics. The technology is expected to improve the understanding of cancer dynamics, facilitating the development of more effective treatment methods. This advancement underscores Bruker's commitment to supporting innovative cancer research.

Bruker Corporation (Nasdaq: BRKR) has completed a majority investment in Acuity Spatial Genomics, Inc., a venture focused on advancing spatial 3D genomics. Acuity's technology, leveraging exclusive innovations from Harvard University, enables genome-wide visualization of chromatin architecture in individual cells. Its OligoFISSEQ™ and OligoFISSEQ HD™ technologies aim to provide insights into gene positioning and regulatory programs critical for understanding diseases. This investment supports Bruker's strategy in spatial biology and enhances research capabilities in oncology, neuroscience, and infectious diseases.

GlycoPath Inc. announced the closing of its seed investment round, securing Bruker Corporation (Nasdaq: BRKR) as a minority investor. The proprietary GlycoTyper™ technology captures diagnostic glycoproteins for analysis using MALDI-TOF mass spectrometry. Aimed at hepatic fibrosis, a rapidly growing disease affecting over 100 million people in the US, the technology promises improvements in early cancer detection and routine surveillance. With high throughput capabilities, it supports research and potential clinical diagnostics in various diseases.

Bruker Corporation (Nasdaq: BRKR) announces advancements in deep plasma proteomics at the virtual 17th US HUPO Conference. Key highlights include presentations on COVID-19 plasma proteomes by Professor Kirk Hansen and new software PaSER v.1.1 for real-time proteomics. Bruker's timsTOF Pro systems demonstrate enhanced sensitivity and dynamic range, crucial for large clinical cohort studies. Additionally, new consumables for structural proteomics, including the PhoX cross-linker, will be available this spring. These developments position Bruker as a leader in proteomics, enhancing diagnostic capabilities.

Bruker Corporation (Nasdaq: BRKR) announced a significant publication in Nature Communications, detailing a study on collisional cross sections (CCS) of peptides. The research, led by Professors Matthias Mann and Fabian Theis, highlights the use of deep learning to predict CCS values from peptide sequences. This advancement may enhance protein identification confidence in proteomics. The study, involving data from five organisms, generated over two million CCS values, positioning it as the most extensive dataset to date. The findings suggest potential applications in various research fields, including biomarker studies.